These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 17877614

  • 1. Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.
    Lescoat G, Chantrel-Groussard K, Pasdeloup N, Nick H, Brissot P, Gaboriau F.
    Cell Prolif; 2007 Oct; 40(5):755-67. PubMed ID: 17877614
    [Abstract] [Full Text] [Related]

  • 2. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.
    Gaboriau F, Leray AM, Ropert M, Gouffier L, Cannie I, Troadec MB, Loréal O, Brissot P, Lescoat G.
    Biometals; 2010 Apr; 23(2):231-45. PubMed ID: 19997770
    [Abstract] [Full Text] [Related]

  • 3. The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox.
    Chantrel-Groussard K, Gaboriau F, Pasdeloup N, Havouis R, Nick H, Pierre JL, Brissot P, Lescoat G.
    Eur J Pharmacol; 2006 Jul 17; 541(3):129-37. PubMed ID: 16765341
    [Abstract] [Full Text] [Related]

  • 4. Iron mobilization, cytoprotection, and inhibition of cell proliferation in normal and transformed rat hepatocyte cultures by the hydroxypyridinone CP411, compared to CP20: a biological and physicochemical study.
    Gaboriau F, Chantrel-Groussard K, Rakba N, Loyer P, Pasdeloup N, Hider RC, Brissot P, Lescoat G.
    Biochem Pharmacol; 2004 Apr 15; 67(8):1479-87. PubMed ID: 15041465
    [Abstract] [Full Text] [Related]

  • 5. Antiproliferative effect of deferiprone on the Hep G2 cell line.
    Chenoufi N, Drénou B, Loréal O, Pigeon C, Brissot P, Lescoat G.
    Biochem Pharmacol; 1998 Aug 15; 56(4):431-7. PubMed ID: 9763218
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Development of tridentate iron chelators: from desferrithiocin to ICL670.
    Nick H, Acklin P, Lattmann R, Buehlmayer P, Hauffe S, Schupp J, Alberti D.
    Curr Med Chem; 2003 Jun 15; 10(12):1065-76. PubMed ID: 12678677
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection.
    Rouan MC, Marfil F, Mangoni P, Séchaud R, Humbert H, Maurer G.
    J Chromatogr B Biomed Sci Appl; 2001 May 05; 755(1-2):203-13. PubMed ID: 11393706
    [Abstract] [Full Text] [Related]

  • 10. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells.
    Glickstein H, El RB, Shvartsman M, Cabantchik ZI.
    Blood; 2005 Nov 01; 106(9):3242-50. PubMed ID: 16020512
    [Abstract] [Full Text] [Related]

  • 11. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
    Harima H, Kaino S, Takami T, Shinoda S, Matsumoto T, Fujisawa K, Yamamoto N, Yamasaki T, Sakaida I.
    BMC Cancer; 2016 Aug 31; 16(1):702. PubMed ID: 27582255
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94.
    Chenoufi N, Hubert N, Loréal O, Morel I, Pasdeloup N, Cillard J, Brissot P, Lescoat G.
    J Hepatol; 1995 Aug 31; 23(2):166-73. PubMed ID: 7499788
    [Abstract] [Full Text] [Related]

  • 14. Modulation of cell proliferation in rat liver cell cultures by new calix[4]arenes.
    Pires VS, Gaboriau F, Guillon J, Nascimento S, Dassonville A, Lescoat G, Desplat V, Rochette J, Jarry C, Sonnet P.
    J Enzyme Inhib Med Chem; 2006 Jun 31; 21(3):261-70. PubMed ID: 16918073
    [Abstract] [Full Text] [Related]

  • 15. Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.
    Chua AC, Ingram HA, Raymond KN, Baker E.
    Eur J Biochem; 2003 Apr 31; 270(8):1689-98. PubMed ID: 12694182
    [Abstract] [Full Text] [Related]

  • 16. Exjade (ICL 670): A new oral iron chelator.
    Agarwal MB.
    J Assoc Physicians India; 2006 Mar 31; 54():214-7. PubMed ID: 16800349
    [Abstract] [Full Text] [Related]

  • 17. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
    Lui GY, Obeidy P, Ford SJ, Tselepis C, Sharp DM, Jansson PJ, Kalinowski DS, Kovacevic Z, Lovejoy DB, Richardson DR.
    Mol Pharmacol; 2013 Jan 31; 83(1):179-90. PubMed ID: 23074173
    [Abstract] [Full Text] [Related]

  • 18. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
    Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A.
    Curr Med Chem; 2005 Jan 31; 12(23):2663-81. PubMed ID: 16305464
    [Abstract] [Full Text] [Related]

  • 19. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE, Hagemann TM.
    Ann Pharmacother; 2006 Jun 31; 40(6):1110-7. PubMed ID: 16735647
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.